From Health Plan Week - A new oral multiple sclerosis (MS) drug that received FDA approval in March has set in motion reviews by health insurers seeking more data on how to handle what could be a blockbuster treatment for the high-cost, chronic disease, health plans and consultants say. At a cost upward of $50,000 a year, the new oral adds to a complex picture for insurers seeking the best care management options for MS at a time the annual inflation rate for MS drugs runs at a rampant 18% per year.
Read more